Cover Image
市場調查報告書

全球癌症生物標記市場分析

Global Cancer Biomarkers Market Research and Analysis 2015-2022

出版商 Orion Market Research Pvt Ltd 商品編碼 486699
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
全球癌症生物標記市場分析 Global Cancer Biomarkers Market Research and Analysis 2015-2022
出版日期: 2017年03月10日 內容資訊: 英文
簡介

本報告提供全球癌症生物標記市場相關調查分析,提供您市場概要,市場影響要素,地區的法規·政策,市場決策要素,收益預測,主要企業簡介和最近的趨勢等系統系資訊。

第1章 報告摘要

第2章 市場概要與考察

  • 定義
  • 分析師,目前市場趨勢
  • 法規
  • 專利分析

第3章 市場決策要素

  • 推動因素
  • 阻礙因素
  • 機會

第4章 市場區隔

  • 生物標記類別
  • 腫瘤類別
  • 各用途
  • 各分析技術

第5章 競爭情形

  • 主要策略分析
  • 主要企業分析

第6章 各地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第7章 企業簡介

  • ABBOTT LABORATORIES
  • AFFYMETRIX, INC.
  • AGENDIA BV
  • AGILENT TECHNOLOGIES, INC.
  • AMBRILIA BIOPHARMA
  • ASTELLAS PHARMA US INC.
  • BECTON, DICKINSON AND COMPANY
  • BECKMAN COULTER INC.
  • BIOCUREX INC.
  • BIOMERIEUX S.A.
  • CLARIENT, INC.
  • DIADEXUS INC.
  • HOLOGIC, INC.
  • ILLUMINA, INC.
  • MERCK & CO. INC.
  • NOVARTIS AG
  • PFIZER, INC.
  • QIAGEN N.V.
  • QUEST DIAGNOSTICS INC.
  • ROCHE DIAGNOSTICS LTD.
目錄
Product Code: BIOT-0409

Market Insights:

Global Cancer biomarkers market is estimated to witness an exponential growth rate of 11.7% during 2017-2022. The growth of the market is backed by the increasing prevalence of cancer coupled with the rising awareness related to the usage of biomarkers at various stages of cancer. According to WHO, Cancer is the leading cause of morbidity as well as mortality at global level with around 14 million new cases registered in 2012. Over the next two decades, the number of new cases of cases if projected to rise by about 70%. Lack of physical activities, improper diet, frequent sun & UV exposure and increasing consumption of tobacco are some of the key factors that have attributed towards the increasing prevalence of cancer. Around 22% of cancer deaths are caused due to tobacco consumption and is regarded as the key risk factor for cancer. Along with it, few internal factors such as genetic mutation, hormonal imbalance and metabolic mutation also contributes towards the rise in cancer cases which in turn boosts the demand for cancer biomarkers. Moreover, increasing demand for clinical diagnosis in cancer's early stages and growing geriatric population base further propels the usage rates of cancer biomarkers. Increasing utilization of the biomarkers in surrogate endpoints & drug targets developments, rising interest among researchers & students regarding cancer diagnostic researchers and growing need for the biomarkers in cancer research are few critical success factors for the growth of the global cancer biomarkers market.

Technological advancements in the omics technology and rising demand for personalized medicine in therapies of cancer are projected to create growth opportunities for the global market which will attribute significantly towards the market value of the cancer biomarkers. However, poor reimbursement policies and high cost associated with cancer biomarkers are the key factors hampering the growth of the global market. Technical issues related to sample collection as well as storage further impede the growth of the global cancer biomarkers market.

Geographical Insights:

Global Cancer biomarkers market can be segmented geographically into North America, Asia Pacific, Europe and RoW. In 2016, North America leads the global cancer biomarkers market followed by Europe and Asia Pacific. The growth of the North American market is driven by the increasing government support for biomarkers discovery and development and growing usage of biomarkers in drug discovery & development by the pharmaceutical companies within the region. Early adoption of the omics technology for the discovery of biomarkers and rising demand for personalized medicine have further propelled the growth of the cancer biomarkers market in North America. Furthermore, Asia Pacific is estimated to witness the highest growth rate owing to the favorable government funding for cancer biomarker research and increasing prevalence of cancer within the regional countries. Rising focus of international players in emerging economies and growing demand for advanced healthcare facilities in developing countries such as China and India are the other key factors that have attributed extensively towards the growth of the cancer biomarkers market in Asia Pacific. Growing awareness related to the benefits of biomarkers in treatment of cancer such as its ability to target the patient specific molecular structure to enhance the early stage of cancer detection & screening as well as to detect the cancer type is also expected to boost the growth of the Asia Pacific market in the upcoming scenario.

The report includes detailed market overview, market determinants, company profiling, sector analysis, market segmentation, geographical analysis, patent analysis, strategic recommendations, key company analysis, gap analysis, key findings, market estimations, market insights, analyst insights and predictive analysis of the market.

Competitive Insights:

The key players of Cancer biomarkers market include Qiagen N.V., Agilent Technologies, Inc., Affymetrix, Inc., Roche Diagnostics Ltd., Illumina, Inc., Merck & Co. Inc., Becton, Dickinson and Company and Pfizer, Inc. The key players are constantly focusing on new product developments as well as upgrading their product portfolios to gain a competitive edge over other players. Product launch, geographic expansion and mergers & acquisitions are some of the key strategies adopted by the market players in the past few years. On January 2017, Qiagen N.V. acquired OmicSoft Corporation that provides access to the OmicSoft's powerful multi-omics data management infrastructure solution and complements Qiagen's bioinformatics portfolio.

Market Segmentation:

  • Cancer biomarkers Market by Biomarker Type
    • Genetic Biomarkers
    • Protein Biomarkers
    • Other Cancer Biomarkers
  • Cancer biomarkers Market by Tumor Type
    • Lung Cancer
    • Prostate Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Cervical Cancer
    • Other Cancers
  • Cancer biomarkers Market by Application
    • Drug Discovery & Development
    • Diagnosis
    • Risk Assessment
    • Prognosis
    • Others
  • Cancer biomarkers Market by Profiling Technologies
    • Omics Technologies
    • Proteomics
    • 2 -D Gel Electrophoresis
    • Mass Spectrometry
    • Imaging Mass Spectrometry
    • Maldi Mass Spectrometry
    • Antibody Array Technology
    • Peptide Array Technology
    • Protein Microarray Technology
    • Genomics
    • Microarrays
    • Next Generation Sequencing
    • PCR
    • Other Omics Technologies
    • Immunoassays
    • Immunohistochemistry
    • ELISA
    • Flow Cytometry
    • Imaging Technologies
    • Positron Emission Tomography
    • Computed Tomography
    • Magnetic Resonance Imaging
    • Mammography
    • Ultrasound
    • Cytogenetics
    • In situ Hybridization
    • Others
    • Bioinformatics

OMR report covers:

  • Comprehensive research methodology of global Cancer biomarkers market
  • In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Cancer biomarkers market
  • Insights about market determinants which are stimulating the global Cancer biomarkers market
  • Detailed and extensive market segments with regional distribution of researched revenues
  • Extensive profiles and recent developments of market players

TABLE OF CONTENTS

1. REPORT SUMMARY

  • 1.1. RESEARCH METHODS AND TOOLS
  • 1.2. MARKET BREAKDOWN
    • 1.2.1. BY SEGMENTS
    • 1.2.2. BY GEOGRAPHY

2. MARKET OVERVIEW AND INSIGHTS

  • 2.1. DEFINITION
  • 2.2. ANALYST & CURRENT MARKET TRENDS
    • 2.2.1. KEY FINDINGS
    • 2.2.2. RECOMMENDATION
    • 2.2.3. CONCLUSION
  • 2.3. REGULATIONS
    • 2.3.1. UNITED STATES
    • 2.3.2. EUROPEAN UNION
    • 2.3.3. CHINA
    • 2.3.4. INDIA
    • 2.3.5. REST OF THE WORLD
  • 2.4. PATENT ANALYSIS

3. MARKET DETERMINANT

  • 3.1. MOTIVATORS
    • 3.1.1. RISING PREVALENCE OF CANCER
    • 3.1.2. GROWING USAGE OF CANCER BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT
    • 3.1.3. TECHNOLOGICAL ADVANCEMENTS
    • 3.1.4. FDA SUPPORT FOR DEVELOPMENT OF BIOMARKERS
    • 3.1.5. IMPROVED ACCURACY & SPEED OF DIAGNOSIS
    • 3.1.6. INCREASING RESEARCH RELATED TO CANCER BIOMARKERS
  • 3.2. RESTRAINTS
    • 3.2.1. LOW BENEFIT-COST RATIO AND HIGH CAPITAL INVESTMENT
    • 3.2.2. LACK OF REGULATORY & REIMBURSEMENT SYSTEMS
    • 3.2.3. TECHNICAL ISSUES RELATED TO SAMPLE STORAGE AND COLLECTION
  • 3.3. OPPORTUNITIES
    • 3.3.1. RISING DEMAND FROM EMERGING ECONOMIES
    • 3.3.2. GROWING TREND TOWARDS PERSONALIZED MEDICINE
    • 3.3.3. COMPANION DIAGNOSTICS

4. MARKET SEGMENTATION

  • 4.1. CANCER BIOMARKERS MARKET BY BIOMARKER TYPE
    • 4.1.1. GENETIC BIOMARKERS
    • 4.1.2. PROTEIN BIOMARKERS
    • 4.1.3. OTHER CANCER BIOMARKERS
  • 4.2. CANCER BIOMARKERS MARKET BY TUMOR TYPE
    • 4.2.1. LUNG CANCER
    • 4.2.2. PROSTATE CANCER
    • 4.2.3. BREAST CANCER
    • 4.2.4. COLORECTAL CANCER
    • 4.2.5. CERVICAL CANCER
    • 4.2.6. OTHER CANCERS
  • 4.3. CANCER BIOMARKERS MARKET BY APPLICATION
    • 4.3.1. DRUG DISCOVERY & DEVELOPMENT
    • 4.3.2. DIAGNOSIS
    • 4.3.3. RISK ASSESSMENT
    • 4.3.4. PROGNOSTICS
    • 4.3.5. OTHERS
  • 4.4. CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGIES
    • 4.4.1. OMICS TECHNOLOGIES
      • 4.4.1.1. PROTEOMICS
        • 4.4.1.1.1. 2-D GEL ELECTROPHORESIS
        • 4.4.1.1.2. MASS SPECTROMETRY
        • 4.4.1.1.2.1. IMAGING MASS SPECTROMETRY
        • 4.4.1.1.2.2. MALDI MASS SPECTROMETRY
        • 4.4.1.1.3. ANTIBODY ARRAY TECHNOLOGY
        • 4.4.1.1.4. PEPTIDE ARRAY TECHNOLOGY
        • 4.4.1.1.5. PROTEIN MICROARRAY TECHNOLOGY
      • 4.4.1.2. GENOMICS
        • 4.4.1.2.1. MICROARRAYS
        • 4.4.1.2.2. NEXT GENERATION SEQUENCING
        • 4.4.1.2.3. PCR
      • 4.4.1.3. OTHER OMICS TECHNOLOGIES
    • 4.4.2. IMMUNOASSAYS
      • 4.4.2.1. IMMUNOHISTOCHEMISTRY
      • 4.4.2.2. ELISA
      • 4.4.2.3. FLOW CYTOMETRY
    • 4.4.3. IMAGING TECNOLOGIES
      • 4.4.3.1. POSITRON EMISSION TOMOGRAPHY
      • 4.4.3.2. COMPUTED TOMOGRAPHY
      • 4.4.3.3. MAGNETIC RESONANCE IMAGING
      • 4.4.3.4. MAMMOGRAPHY
      • 4.4.3.5. ULTRASOUND
    • 4.4.4. CYTOGENETICS
      • 4.4.4.1. IN SITU HYBRIDIZATION
      • 4.4.4.2. OTHERS
    • 4.4.5. BIOINFORMATICS

5. COMPETITIVE LANDSCAPE

  • 5.1. KEY STRATEGY ANALYSIS
  • 5.2. KEY COMPANY ANALYSIS 

6. REGIONAL ANALYSIS

  • 6.1. NORTH AMERICA
    • 6.1.1. UNITED STATES
    • 6.1.2. CANADA
    • 6.1.3. REST OF NORTH AMERICA
  • 6.2. EUROPE
    • 6.2.1. UNITED KINGDOM
    • 6.2.2. FRANCE
    • 6.2.3. GERMANY
    • 6.2.4. ITALY
    • 6.2.5. SPAIN
    • 6.2.6. REST OF EUROPE
  • 6.3. ASIA PACIFIC
    • 6.3.1. INDIA
    • 6.3.2. CHINA
    • 6.3.3. JAPAN
    • 6.3.4. REST OF ASIA PACIFIC
  • 6.4. REST OF THE WORLD

7. COMPANY PROFILES

  • 7.1. ABBOTT LABORATORIES
    • 7.1.1. INTRODUCTION
    • 7.1.2. ABBOTT LABORATORIES PRODUCT PORTFOLIO
    • 7.1.3. ABBOTT LABORATORIES RECENT ACTIVITIES
  • 7.2. AFFYMETRIX, INC.
    • 7.2.1. INTRODUCTION
    • 7.2.2. AFFYMETRIX, INC. PRODUCT PORTFOLIO
    • 7.2.3. AFFYMETRIX, INC. RECENT ACTIVITIES
  • 7.3. AGENDIA BV
    • 7.3.1. INTRODUCTION
    • 7.3.2. AGENDIA BV PRODUCT PORTFOLIO
    • 7.3.3. AGENDIA BV RECENT ACTIVITIES
  • 7.4. AGILENT TECHNOLOGIES, INC.
    • 7.4.1. INTRODUCTION
    • 7.4.2. AGILENT TECHNOLOGIES, INC. PRODUCT PORTFOLIO
    • 7.4.3. AGILENT TECHNOLOGIES, INC. RECENT ACTIVITIES
  • 7.5. AMBRILIA BIOPHARMA
    • 7.5.1. INTRODUCTION
    • 7.5.2. AMBRILIA BIOPHARMA PRODUCT PORTFOLIO
    • 7.5.3. AMBRILIA BIOPHARMA RECENT ACTIVITIES
  • 7.6. ASTELLAS PHARMA US INC.
    • 7.6.1. INTRODUCTION
    • 7.6.2. ASTELLAS PHARMA US INC. PRODUCT PORTFOLIO
    • 7.6.3. ASTELLAS PHARMA US INC. RECENT ACTIVITIES
  • 7.7. BECTON, DICKINSON AND COMPANY
    • 7.7.1. INTRODUCTION
    • 7.7.2. BECTON, DICKINSON AND COMPANY PORTFOLIO
    • 7.7.3. BECTON, DICKINSON AND COMPANY RECENT ACTIVITIES
  • 7.8. BECKMAN COULTER INC.
    • 7.8.1. INTRODUCTION
    • 7.8.2. BECKMAN COULTER INC. PRODUCT PORTFOLIO
    • 7.8.3. BECKMAN COULTER INC. RECENT ACTIVITIES
  • 7.9. BIOCUREX INC.
    • 7.9.1. INTRODUCTION
    • 7.9.2. BIOCUREX INC. PRODUCT PORTFOLIO
    • 7.9.3. BIOCUREX INC. RECENT ACTIVITIES
  • 7.10. BIOMERIEUX S.A.
    • 7.10.1. INTRODUCTION
    • 7.10.2. BIOMERIEUX S.A. PRODUCT PORTFOLIO
    • 7.10.3. BIOMERIEUX S.A. RECENT ACTIVITIES
  • 7.11. CLARIENT, INC.
    • 7.11.1. INTRODUCTION
    • 7.11.2. CLARIENT, INC. PRODUCT PORTFOLIO
    • 7.11.3. CLARIENT, INC. RECENT ACTIVITIES
  • 7.12. DIADEXUS INC.
    • 7.12.1. INTRODUCTION
    • 7.12.2. DIADEXUS INC. PRODUCT PORTFOLIO
    • 7.12.3. DIADEXUS INC. RECENT ACTIVITIES
  • 7.13. HOLOGIC, INC.
    • 7.13.1. INTRODUCTION
    • 7.13.2. HOLOGIC, INC. PRODUCT PORTFOLIO
    • 7.13.3. HOLOGIC, INC. RECENT ACTIVITIES
  • 7.14. ILLUMINA, INC.
    • 7.14.1. INTRODUCTION
    • 7.14.2. ILLUMINA, INC. PRODUCT PORTFOLIO
    • 7.14.3. ILLUMINA, INC. RECENT ACTIVITIES
  • 7.15. MERCK & CO. INC.
    • 7.15.1. INTRODUCTION
    • 7.15.2. MERCK & CO. INC. PRODUCT PORTFOLIO
    • 7.15.3. MERCK & CO. INC. RECENT ACTIVITIES
  • 7.16. NOVARTIS AG
    • 7.16.1. INTRODUCTION
    • 7.16.2. NOVARTIS AG PRODUCT PORTFOLIO
    • 7.16.3. NOVARTIS AG RECENT ACTIVITIES
  • 7.17. PFIZER, INC.
    • 7.17.1. INTRODUCTION
    • 7.17.2. PFIZER, INC. PRODUCT PORTFOLIO
    • 7.17.3. PFIZER, INC. RECENT ACTIVITIES
  • 7.18. QIAGEN N.V.
    • 7.18.1. INTRODUCTION
    • 7.18.2. QIAGEN N.V. PRODUCT PORTFOLIO
    • 7.18.3. QIAGEN N.V. RECENT ACTIVITIES
  • 7.19. QUEST DIAGNOSTICS INC.
    • 7.19.1. INTRODUCTION
    • 7.19.2. QUEST DIAGNOSTICS INC. PRODUCT PORTFOLIO
    • 7.19.3. QUEST DIAGNOSTICS INC. RECENT ACTIVITIES
  • 7.20. ROCHE DIAGNOSTICS LTD.
    • 7.20.1. INTRODUCTION
    • 7.20.2. ROCHE DIAGNOSTICS LTD. PRODUCT PORTFOLIO
    • 7.20.3. ROCHE DIAGNOSTICS LTD. RECENT ACTIVITIES

List of Tables

  • TABLE # 1 GLOBAL CANCER BIOMARKERS MARKET RESEARCH AND ANALYSIS, BY BIOMARKER TYPE 2015-2022 ($ MILLION)
  • TABLE # 2 GLOBAL GENETIC BIOMARKERS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 3 GLOBAL PROTEIN BIOMARKERS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 4 GLOBAL OTHER CANCER BIOMARKERS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 5 GLOBAL CANCER BIOMARKERS MARKET RESEARCH AND ANALYSIS, BY TUMOR TYPE 2015-2022 ($ MILLION)
  • TABLE # 6 GLOBAL LUNG CANCER MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 7 GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 8 GLOBAL BREAST CANCER MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 9 GLOBAL COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 10 GLOBAL CERVICAL CANCER MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 11 GLOBAL OTHER CANCER MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 12 GLOBAL CANCER BIOMARKERS MARKET RESEARCH AND ANALYSIS, BY APPLICATION 2015-2022 ($ MILLION)
  • TABLE # 13 GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 14 GLOBAL DIAGNOSIS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 15 GLOBAL RISK ASSESSMENT MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 16 GLOBAL PROGNOSIS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 17 GLOBAL OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 18 GLOBAL CANCER BIOMARKERS MARKET RESEARCH AND ANALYSIS, BY PROFILING TECHNOLOGIES 2015-2022 ($ MILLION)
  • TABLE # 19 GLOBAL OMICS TECHNOLOGIES MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 20 GLOBAL PROTEOMICS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 21 GLOBAL 2-D GEL ELECTROPHORESIS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 22 GLOBAL MASS SPECTROMETRY MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 23 GLOBAL IMAGING MASS SPECTROMETRY MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 24 GLOBAL MALDI MASS SPECTROMETRY MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 25 GLOBAL ANTIBODY ARRAY TECHNOLOGY MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 26 GLOBAL PEPTIDE ARRAY TECHNOLOGY MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 27 GLOBAL PROTEIN MICROARRAY TECHNOLOGY MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 28 GLOBAL GENOMICS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 29 GLOBAL MICROARRAYS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 30 GLOBAL NEXT GENERATION SEQUENCING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 31 GLOBAL PCR MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 32 GLOBAL OTHER OMICS TECHNOLOGIES MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 33 GLOBAL IMMUNOASSAYS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 34 GLOBAL IMMUNOHISTOCHEMISTRY MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 35 GLOBAL ELISA MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 36 GLOBAL FLOW CYTOMETRY MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 37 GLOBAL IMAGING TECHNOLOGIES MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 38 GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 39 GLOBAL COMPUTED TOMOGRAPHY MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 40 GLOBAL MAGNETIC RESONANCE IMAGING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 41 GLOBAL MAMMOGRAPHY MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 42 GLOBAL ULTRASOUND MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 43 GLOBAL CYTOGENETICS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 44 GLOBAL IN SITU HYBRIDIZATION MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 45 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 46 GLOBAL BIOINFORMATICS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
  • TABLE # 47 ABBOTT LABORATORIES PRODUCT PORTFOLIO
  • TABLE # 48 ABBOTT LABORATORIES RECENT ACTIVITIES
  • TABLE # 49 AFFYMETRIX, INC. PRODUCT PORTFOLIO
  • TABLE # 50 AFFYMETRIX, INC. RECENT ACTIVITIES
  • TABLE # 51 AGENDIA BV PRODUCT PORTFOLIO
  • TABLE # 52 AGENDIA BV RECENT ACTIVITIES
  • TABLE # 53 AGILENT TECHNOLOGIES, INC. PRODUCT PORTFOLIO
  • TABLE # 54 AGILENT TECHNOLOGIES, INC. RECENT ACTIVITIES
  • TABLE # 55 AMBRILIA BIOPHARMA PRODUCT PORTFOLIO
  • TABLE # 56 AMBRILIA BIOPHARMA RECENT ACTIVITIES
  • TABLE # 57 ASTELLAS PHARMA US INC. PRODUCT PORTFOLIO
  • TABLE # 58 ASTELLAS PHARMA US INC. RECENT ACTIVITIES
  • TABLE # 59 BECTON, DICKINSON AND COMPANY PORTFOLIO
  • TABLE # 60 BECTON, DICKINSON AND COMPANY RECENT ACTIVITIES
  • TABLE # 61 BECKMAN COULTER INC. PRODUCT PORTFOLIO
  • TABLE # 62 BECKMAN COULTER INC. RECENT ACTIVITIES
  • TABLE # 63 BIOCUREX INC. PRODUCT PORTFOLIO
  • TABLE # 64 BIOCUREX INC. RECENT ACTIVITIES
  • TABLE # 65 BIOMERIEUX S.A. PRODUCT PORTFOLIO
  • TABLE # 66 BIOMERIEUX S.A. RECENT ACTIVITIES
  • TABLE # 67 CLARIENT, INC. PRODUCT PORTFOLIO
  • TABLE # 68 CLARIENT, INC. RECENT ACTIVITIES
  • TABLE # 69 DIADEXUS INC. PRODUCT PORTFOLIO
  • TABLE # 70 DIADEXUS INC. RECENT ACTIVITIES
  • TABLE # 71 HOLOGIC, INC. PRODUCT PORTFOLIO
  • TABLE # 72 HOLOGIC, INC. RECENT ACTIVITIES
  • TABLE # 73 ILLUMINA, INC. PRODUCT PORTFOLIO
  • TABLE # 74 ILLUMINA, INC. RECENT ACTIVITIES
  • TABLE # 75 MERCK & CO. INC. PRODUCT PORTFOLIO
  • TABLE # 76 MERCK & CO. INC. RECENT ACTIVITIES
  • TABLE # 77 NOVARTIS AG PRODUCT PORTFOLIO
  • TABLE # 78 NOVARTIS AG RECENT ACTIVITIES
  • TABLE # 79 PFIZER, INC. PRODUCT PORTFOLIO
  • TABLE # 80 PFIZER, INC. RECENT ACTIVITIES
  • TABLE # 81 QIAGEN N.V. PRODUCT PORTFOLIO
  • TABLE # 82 QIAGEN N.V. RECENT ACTIVITIES
  • TABLE # 83 QUEST DIAGNOSTICS INC. PRODUCT PORTFOLIO
  • TABLE # 84 QUEST DIAGNOSTICS INC. RECENT ACTIVITIES
  • TABLE # 85 ROCHE DIAGNOSTICS LTD. PRODUCT PORTFOLIO
  • TABLE # 86 ROCHE DIAGNOSTICS LTD. RECENT ACTIVITIES

List of Figures

  • FIGURE # 1 NORTH AMERICA MARKET RESEARCH AND ANALYSIS, 2015-2022
  • FIGURE # 2 US MARKET RESEARCH AND ANALYSIS, 2015-2022
  • FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2022
  • FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2022
  • FIGURE # 5 UK MARKET RESEARCH AND ANALYSIS, 2015-2022
  • FIGURE # 6 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2022
  • FIGURE # 7 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2022
  • FIGURE # 8 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2022
  • FIGURE # 9 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2022
  • FIGURE # 10 ROE MARKET RESEARCH AND ANALYSIS, 2015-2022
  • FIGURE # 11 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2022
  • FIGURE # 12 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2022
  • FIGURE # 13 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2022
  • FIGURE # 14 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2022
  • FIGURE # 15 ROAPAC MARKET RESEARCH AND ANALYSIS, 2015-2022
  • FIGURE # 16 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2022
Back to Top